¤¦¤ÄÉ¡¦µ¤Ê¬¾ã³²¥°¥ë¡¼¥×
¥°¥ë¡¼¥×¥ê¡¼¥À¡¼¡§²ÃÆ£ Àµ¼ù
¤¦¤ÄÉ¡¦ÁжËÀ¾ã³²¤Î¼£ÎÅ¥¨¥Ó¥Ç¥ó¥¹¤ÎÃßÀѤȼ£ÎÅÀºÅ٤θþ¾å¡¢¸ÄÊ̲½°åÎÅ¡ÊPersonalized Medicine¡Ë¤Î¤¿¤á¤Î¥¢¥ë¥´¥ê¥º¥à¤Î¹½ÃÛ¤òÌܻؤ·¤¿¸¦µæ¥°¥ë¡¼¥×¤Ç¤¹¡£
̵ºî°Ù³ä¤êÉÕ¤±»î¸³(RCT)¤ò·Ñ³¤·¤Æ¹Ô¤Ã¤Æ¤ª¤ê¡¢¸½ºß¤Ï¡¢Ì¤¼£ÎŤΤ¦¤ÄÉ¡¢¼£ÎÅÄñ¹³À¤¦¤ÄÉ¡¢ÁжËÀ¤¦¤ÄɤòÂоݤȤ·¤¿RCT¤¬¿Ê¹ÔÃæ¤Ç¤¹¡£Â¾¤Ë¤â¤¦¤ÄɤοÇÃǤ伣ÎŤËÌò¤ËΩ¤Ä¥Ð¥¤¥ª¥Þ¡¼¥«¡¼¤äÇØ·Ê°ø»Ò¤Ê¤É¤Îõº÷¤ò¹Ô¤Ã¤Æ¤ª¤ê¤Þ¤¹¡£
¤³¤ì¤éRCT¤Î·ë²Ì¤ò¡¢¥²¥Î¥àÌôÍý¡¢¥Ë¥å¡¼¥í¥Õ¥£¥¸¥ª¥í¥¸¡¼¤Ê¤É¤Î²òÀÏÊýË¡¤òÍѤ¤¤Æ¡¢³Æ¥°¥ë¡¼¥×¤Ç¹¹¤Ê¤ë¸¡Æ¤¤ò¹Ô¤Ã¤Æ¤¤¤Þ¤¹¡£
- ¤¦¤ÄɤθÄÊ̲½¼£ÎÅ¥¢¥ë¥´¥ê¥º¥à»î¸³¡¨Genotype Utility Needed for Depression Antidepressant Medication (GUNDAM study¡¨UMINÅÐÏ¿ÈÖ¹æ000006417)
- º®¹çÀ¤¦¤ÄɤÎ̵ºî°Ù³äÉÕÈæ³Ó»î¸³¡¢¥Ð¥¤¥ª¥Þ¡¼¥«¡¼¤Ë´ð¤Å¤¯¸ÄÊ̲½¼£ÎŤδðÈ×¹½ÃÛ(REMIX study¡¨UMIN000020735¡Ë
- ·ÐƬ³¸Ä¾Î®Åŵ¤»É·ã(tDCS)Á°¸å¤Ë¤ª¤±¤ë¤¦¤ÄÉ´µ¼Ô¤ÎǧÃε¡Ç½¤ÈǾÇÈÊѲ½¤Î¸¡¾Ú¡¡(CEED-D study:UMIN000015046¡Ë
¥°¥ë¡¼¥×¤Î¼ç¤Ê¶ÈÀÓ¡¦Ãø½ñ
ÏÀʸ
- Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. Journal of Psychiatric Research 2017
- Polymorphism of rs3813034 in serotonin transporter gene SLC6A4 is associated with the SSRI/SNRI response in depressive disorder: sequencing analysis of SLC6A4 Journal of Clinical Psychopharmacology 2016
- Genetic variants in combination with early partial improvement as clinical utility predictor of treatment outcome in major depressive disorder. - The result of two pooled RCT – Translational Psychiatry 2015
- The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Translational Psychiatry , 2015
- 5-HTTLPR rs25531A>G differentially influence paroxetine and fluvoxamine antidepressant efficacy: A randomized-controlled trial. Journal of Clinical Psychopharmacology¡¡2013
- Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression.Psychiatry Res. 2012
- Review and Meta-Analysis of Antidepressant Pharmacogenetic Findings in Major Depressive Disorder, Mol Psychiatry 2010
- Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsychopharmacol. 2009
- Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2009
- The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Journal of Clinical Psychopharmacology 2008
- ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008
- Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 2008
- Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007
- T. Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients. Neuropsychobiology 2006
- Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005
Ãø½ñ
- ¥¬¥¤¥É¥é¥¤¥ó³°Íè¿ÇÎÅ¡¡Àº¿À¿´¿È°å³Ø¼À´µ¡¨44¤¦¤ÄÉÂÆü·Ð¥á¥Ç¥£¥«¥ë³«È¯,2016
- Àº¿À²ÊÌôʪÎÅË¡¡¡¥°¥Ã¥É¥×¥é¥¯¥Æ¥£¥¹¡¡Àº¿À¿À·Ð³Ø²ñÊÔ¡¡£Ö¾Ï¡¡¹³¤¦¤ÄÌô
- Àº¿À¼À´µ¤Î¥Ð¥¤¥ª¥Þ¡¼¥«¡¼¡¨9.Ìôʪȿ±þÀ¤Î¥Ð¥¤¥ª¥Þ¡¼¥«¡¼ 9-1.¹³¤¦¤ÄÌô
- ¿À·Ð¡¦Àº¿À¼À´µ¼£Îťޥ˥奢¥ëº.¤è¤¯¤ß¤é¤ì¤ëÀº¿À¼À´µ; ÁжËÀ¾ã³²¡¡ÆüËÜ°å»Õ²ñ,2013
- µ¤Ê¬¾ã³²¤ÎÌôÍý¡¦À¸²½³Ø¡½¤¦¤ÄɤÎǾÆâ¥á¥«¥Ë¥º¥à¸¦µæ¡¡¿ÊÊâ¤ÈÄ©À¡¡Âè6¾Ï¡¡¥²¥Î¥à¡¢¤¦¤Äɼ£ÎÅÈ¿±þÀ¤òµ¬Äꤹ¤ëÍ×°ø¡¦°äÅÁ»Òí¯¤¦¤ÄɤÎÌôÍý¡¦À¸²½³ØŪ¸¦µæº©ÏòñÊÔ
¹Ö±é
- ¤¦¤Äɤˤª¤±¤ë¹³¤¦¤ÄÌô¤ÎÈ¿±þͽ¬¤È»È¤¤Ê¬¤±-From Research to Clinical-¡¢
Âè107²óÆüËÜÀº¿À¿À·Ð³Ø²ñ³Ø½ÑÁí²ñ¡¡¶µ°é¹Ö±é ¤Ê¤É